Generex Subsidiary Antigen Express Receives Patent in China for Its Ii-Key Peptide Vaccine Technology

Generex Biotechnology Corporation announced that it has received notice of issuance of a patent on its Ii-Key peptide technology in China. This expands a solid intellectual property estate that includes both broad claims covering its technology as well as specific Ii-Key-containing drug development compounds. Additionally, management is actively seeking potential joint venture/licensing partnerships for its peptide cancer vaccine technology platform and is in active discussions with several large pharmaceutical companies.

 
The Company recently reported interim results from a Phase II trial of an Ii-Key modified peptide vaccine for patients treated for breast cancer who are at high risk of relapse. While there was a 7% relapse rate in the control arm there were no relapses in the Ii-Key peptide arm (AE37) when analyzed at the 13-month time point. A review article co-authored by Eric von Hofe, Ph.D., President of Antigen Express entitled ‘A New Era in Anticancer Peptide Vaccines’, appeared in the journal Cancer, published by the American Cancer Society.